1. (Amended) A kit of parts for delivery of a gene to a recipient cell in a host using a gene delivery vehicle to which a humoral response can be raised, said kit comprising a first composition of a first gene delivery vehicle comprising a nucleic acid comprising a gene to be delivered to said recipient cell and a second composition of a second gene delivery vehicle, said second gene delivery vehicle essentially identical to said first gene delivery vehicle, but lacking said gene to be delivered.

2. (Amended) The kit of parts according to claim 1, wherein said second composition is a vaccine and wherein said first composition is a composition for gene therapy.

3. (Amended) The kit of parts according to claim 2, wherein said vaccine is administered at a time before said first composition sufficient for the host to raise a neutralising humoral response to said second gene delivery vehicle.

5. (Amended twice) The kit of parts according to claim 1, wherein said first gene delivery vehicle and said second gene delivery vehicle are of adenoviral origin.

7. (Amended) A method for delivering a gene of interest to a recipient cell in a host using a gene delivery vehicle comprising a nucleic acid comprising said gene of interest, said method comprising:

administering to a host a vaccine composition comprising a first gene delivery vehicle lacking said gene of interest;

allowing for a neutralizing humoral response to be raised by said host to said first gene delivery vehicle; and

administering a composition for gene therapy comprising a second gene delivery vehicle having a nucleic acid comprising said gene of interest in an amount greater than an amount which can be neutralized by said humoral response, said first gene delivery vehicle and said second gene delivery vehicle being cross-reactive.

8. (Amended) A method for minimizing liver toxicity in a host of a gene delivery composition upon

administration, said method comprising:

administering to a host a vaccine composition comprising a first gene delivery vehicle lacking a gene of interest;

allowing for a neutralizing humoral response to be raised by said host to said first gene delivery vehicle; and

administering a composition for gene therapy comprising a second gene delivery vehicle having a nucleic acid comprising said gene of interest to be delivered to said host in an amount greater than an amount which can be neutralized by said humoral response, said first gene delivery vehicle and said second gene delivery vehicle having the same serotype.

9. (Amended twice) The method according to claim 7, wherein said first gene delivery vehicle and said second gene delivery vehicle are of adenoviral origin.

10. (Amended twice) A method of preparing a pharmaceutical comprising providing the kit of parts according to claim 1 together with a pharmaceutically acceptable carrier.

13. (Amended twice) The kit of parts according to claim 1, wherein said gene to be delivered is interleukin.

Please add the following new claims:

27. (New) The kit of parts according to claim 1, wherein said second gene delivery vehicle is to be administered at a time before said first composition at a time sufficient for the host to raise a neutralising humoral response to said second gene delivery vehicle.

28. (New) The kit of parts according to claim 2, wherein said first gene delivery vehicle and said second gene delivery vehicle are of adenoviral origin.

29. (New) The kit of parts according to claim 3, wherein said first gene delivery vehicle and said

second gene delivery vehicle are of adenoviral origin.

30. (New) The method according to claim 8, wherein said first gene delivery vehicle and said second gene delivery vehicle are of adenoviral origin.

31. (New) The kit of parts according to claim 2, wherein said gene to be delivered is interleukin-3.

32. (New) The kit of parts according to claim 3, wherein said gene to be delivered is interleukin-3.

33. (New) The kit of parts according to claim 5, wherein said gene to be delivered is interleukin-3.

34. (New) The method of claim 7, wherein said administering said composition for gene therapy occurs at least fourteen days after said administering said vaccine composition.

35. (New) The method of claim 7, further comprising administering a second dose of said vaccine composition prior to said administrating said composition for gene therapy.

36. (New) The method of claim 8, wherein said administering said composition for gene therapy occurs at least fourteen days after said administering said vaccine composition.

37. (New) The method of claim 8, further comprising administering a second dose of said vaccine composition prior to said administrating said composition for gene therapy.

Respectfully submitted,

Krista Weber Powell
Registration No. 47,867
Attorney for Applicants
TRASKBRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: July 22, 2002